As companies with lung cancer immunotherapies process the small level detail they received on the outcome of August's PBAC meeting at which the committee considered simplifying their reimbursement, AstraZeneca has announced new and positive results from its yet-to-be-listed IMFINZI (durvalumab). …
Latest Video
New Stories
-
Budget outcome confirms jump in pharmaceutical spend
September 25, 2020 - - Latest News -
The COVID-19 vaccine manufacturing and supply deals
September 25, 2020 - - Latest News -
PBAC looking for a new consumer representative
September 25, 2020 - - Latest News -
'At some point, we have to trust somebody'
September 25, 2020 - - Latest News -
Government hits the industry with new savings options
September 24, 2020 - - Latest News -
BIO's Joe Damond: US sending industry a signal about pricing in other markets
September 24, 2020 - - Latest News -
New white paper highlights need for action on AMR
September 24, 2020 - - Latest News